Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Certainly in the sense the FX trial failed. If it was successful shares would be > $10
No idea why they never did a skin partnership, seems like a good strategy
Yes, they will begin the analysis at that point and no idea how long it takes for 150+ patients. Surprising it takes a month considering it is a database and wouldn't they be able to run queries and generate data quickly.
I only interpret that they expect the study to be a fail and want to sell or are they willing to sell a controlling stake much cheaper than what a successful CX trial could fetch.
I wonder if this tanks Monday.
Did ChessMaster bail on it too, like that Mike pumper dude on SA & Twitter? Wondering if nothing here. Lots of patients finished treatments months ago. They have/had Cirrhosis, not like they can wait around for some report of a drug that likely is a failure when they have a chronic condition.
Stock is $1.67
Probably downside to $.30, upside to $25+ or if they can register $80-100
Low probability based on market, maybe a sense that doesn't work. Who knows.
Was the reference to the 3 AD patients having 50% improvement significant or not? Is the REGN drug delivering much better results?
Also, they still make all references from other companies as "informal," so implies nothing is close.
It really depends on how well it works. Minimal improvement will be higher, huge benefits, like reversing cirrhosis in some patients would be huge and it could spike major. I can see anywhere from $8-80
Early 2018 for combo therapy next readout, after CX readout
Hard to know, any interested in GR-MD-02 if CX fails, maybe, but stock very low. Could be $10, 20+ if CX data is real strong.
Doesn't seem very encouraging given the longs are no longer writing SA blog posts, they haven't been able to land a partner and overall share price.
Yes, why no partnerships to explore other Gal-3 indications? Skin, cancer, other fibrosis,etc
No, not sure there is one. I thought there was going to be one too.
Not a bad strategy. How much are $5 calls? Certainly if data are good it should go much higher than $5.
The skin partnership would put a floor under the shares.
Maybe for leverage purposes, but the need one for sales & distribution. Would take huge && and time to build a team to do that.
Maybe not for the trial, but definitely for any actual marketing and distribution.
Seems like getting a partner for the skin conditions can accelerate those studies and then the partner has an option for other indications like NASH CX, other fibrosis, I-O.
I would imagine they will get a partner to market and distribute it
That's why I'd like to see a partnership for skin conditions with an option for other indications. That way they could go to market quickly.
Also, does GALT have an ability to manufacture GR-MD-02 in volume if necessary?
Not getting to $10 without either a major partnership or great CX readout
Galecto results are 2 days old, not sure why they'd have an effect now
Doesn't it say Ullhein is selling for a max. price of $2.39, below Friday's close?
ATM is only $30M of the $100M
I don't think it's awful if you do it gradually
Bigger question is what about the other $70M and why is large shareholder selling 80% of his holdings in low $2s and no riding out to see CX readout
Also, read the PR closely where they mention companies are inquiring, but just informally.
That implies a partnership is nowhere close.
Also, read the PR closely where they mention companies are inquiring, but just informally.
That implies a partnership is nowhere close.
If they have the money to get through December then worry about capital after that. In reality, if it fails just close the doors. If it's a success they can raise at much higher prices while they determine next steps.
It seems like they will try and just keep going regardless with little regard for shareholder value.
And as someone posted on another board it doesn't seem like a partnership is close.
They could vary for indications. GR-MD-02 is in combo for Melanoma, Neck and Head.
Can someone elaborate, would that basically mean if the CC trial is successful they could file a NDA immediately vs. having to do further trials?
they need the skin partnership to protect the downside. even if the CX trial fails if they still have AD, Psoriasis and possibly I-O combo studies this could still be worth $3-5 pending some successful studies and potential approvals.
No idea but heavy volume again. I would expect a skin partnership first, but who knows, maybe those talks are advancing to more of a buyout like TBRA with milestone payments.
Does NVS taking the option trigger any immediate payments or just sharing trial costs? If the payments are milestone based they are only paying when good results are achieved, which is in theory beneficial to them.
Any PTs if they do excercis it? $8-10 or even higher
A news story now on upgrade
Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst'
http://finance.yahoo.com/news/galectin-shares-upgraded-buy-nash-124621801.html
Wainwright upgrades to Buy and raises PT to $3.50 from $.60
I don't have the note, but an impressive increase % wise
AD is projected as a very large market opportunity, hopefully enough to get a partnership to pursue further studies. That would move the shares a few points maybe.
http://www.fiercepharma.com/marketing/dupilumab-data-sanofi-regeneron-gear-up-for-potential-5b-sales
Chess,
What do you make of the complexity with getting a partner for AD? Also, it sounds like they are not pursuing anything with Psoriasis.
Maybe, but without news on a partnership I don't think it will go much higher until December. Hang around $3 prior to the readout.
I thought the 2018 trial was registration eligible? Why would it then take until 2021 to reach the market?
Need the partnership for the skin condition. Hopefully they provide some
Insight on the call next week.
It sounds like they may target extreme forms. REGN is up for approval soon on an AD therapy.
Have to get a partnership for the skin conditions, not really even a factor until we hear on that.
If they do a partnership that finds Skin studies and even if CX fails their burn will probably only be $5-7M annually so they want have to go crazy while they wait on Skins ones and pursue I-O partnerships.
The studies are what cost a fortune. They wouldn't be doing those at that point.
Good point. Unless they get a great offer they may just try and do a partnership for the skin conditions to continue the studies and wait for the CX readout.
If the CX readout is poor they can just support their partner and also try for a partnership on I-O. Not as big as a score, but maybe the Melanoma and AD are worth $8 and then I-O another $5-10.
Good point. Unless they get a great offer they may just try and do a partnership for the skin conditions to continue the studies and wait for the CX readout.
If the CX readout is poor they can just support their partner and also try for a partnership on I-O. Not as big as a score, but maybe the Melanoma and AD are worth $8 and then I-O another $5-10.